title: Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children.
abstract: The bioavailability of didanosine at 180 mg/m(2) once daily was compared to that at 90 mg/m(2) twice daily in 24 children with advanced human immunodeficiency virus infection. Children were studied at steady state using optimal sampling and prior pharmacokinetic parameter estimates. Relative bioavailability was 0. 95 +/- 0.49, supporting the potential clinical adequacy of once-daily dosing.
authors.affiliation: Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: T
authors.initials: T
authors.lastname: Abreu
authors.forename: K
authors.initials: K
authors.lastname: Plaisance
authors.forename: V
authors.initials: V
authors.lastname: Rexroad
authors.forename: S
authors.initials: S
authors.lastname: Nogueira
authors.forename: R H
authors.initials: RH
authors.lastname: Oliveira
authors.forename: L A
authors.initials: LA
authors.lastname: Evangelista
authors.forename: R
authors.initials: R
authors.lastname: Rangel
authors.forename: I S
authors.initials: IS
authors.lastname: Silva
authors.forename: C
authors.initials: C
authors.lastname: Knupp
authors.forename: J S
authors.initials: JS
authors.lastname: Lambert
mesh_terms: D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D001682:Biological Availability; D002648:Child; D002675:Child, Preschool; D016049:Didanosine / Q000493:pharmacokinetics*; D015658:HIV Infections / Q000378:metabolism*; D006801:Humans
chemical_list: D019380:Anti-HIV Agents; D016049:Didanosine